Drug profile

The FDA adverse-event record for Unspecified Treatments

25 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Treatments. Species, reactions, and outcomes follow.

#1607 of 2,679
by report volume (all drugs)
25
adverse-event reports
32.0%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Unspecified Treatments ranks #1577 of 2679 by total reports (25). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1577
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Unspecified Treatments has 25 reports now versus 24 in that prior snapshot: 1 more (4.2%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Unspecified Treatments changes

Signature read: Unspecified Treatments's 32.0% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
8
Deaths Reported
32.0%
Death-coded share of reports

Active Ingredients

Unspecified Treatments

Administration Routes

UnknownTopical

Species Affected

Dog 15
Cat 8
Cockatiel 1
Other Birds 1

Most Affected Breeds

Domestic Shorthair 7
Retriever - Labrador 2
Siberian Husky 2
Coonhound - Black and Tan 1
Beagle 1
Unknown 1
Other Birds (other) 1
Terrier - Yorkshire 1
Dachshund - Standard Smooth-haired 1
Domestic Mediumhair 1

Most Reported Reactions

Vomiting 8
Lethargy (see also Central nervous system depression in Neurological) 5
Decreased appetite 5
Death 4
Death by euthanasia 4
Pain NOS 3
Hyperglycaemia 3
Elevated alanine aminotransferase (ALT) 3
Pancreatitis 3
Not eating 3
Leucocytosis NOS 3
Diarrhoea 3

Outcome Breakdown

Ongoing
11 (44.0%)
Recovered/Normal
5 (20.0%)
Died
4 (16.0%)
Euthanized
4 (16.0%)
Outcome Unknown
1 (4.0%)

Unspecified Treatments: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Unspecified Treatments (#1607 of 2,679 by report volume); death-coded 32.0%. PlainBreed drug row · death-coded share stamp 32.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →